Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group

13. Skin - guidance

To access BNF Formulary section click on the link under BNF Section/s

To access the Guidance Document click on the highlighted text under the Title column

Use documents past their review date with Caution

BNF Section/s Title Issuing Body  Date of Issue Update Due
13.3.1.4  Abrocitinib
High-Cost Drugs     
13.3.1.4  Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis TA814 NICE Aug 2022  
13.3.1.4  Baricitinib   High-Cost Drugs     
13.3.1.4 Baricitinib -  Baricitinib for treating moderate to severe atopic dermatitis TA681 NICE Mar 2021 2024
13.3.1.4  Deucravacitinib
High-Cost Drugs    
13.3.1.4  Deucravacitinib - Deucravacitinib for treating moderate to severe plaque psoriasis NICE Jun 2023  
13.1 Emollients - Emollient Prescribing Guidance for Adults and Children Kent & Medway ICB Oct 2023 Oct 2025
13.1 Emollients - Patient Leaflet Emollients and How to Use Them   Version 1.0 Kent & Medway ICB Oct 2023 Oct 2025
13.1 Emollients - Position statement on Bath and Shower preparations / additives Kent & Medway ICB Oct 2023 Oct 2025
13.1 Emollients - Patient Information Leaflet on Bath & Shower Preparations Kent & Medway ICB Oct 2023 Oct 2025
13.1.1 Epimax  - Epimax Ointment and Epimax Paraffin-Free Ointment: reports of ocular surface toxicity and ocular chemical injury MHRA 
Drug Safety Update
Jul 2024 -
13.4. Hyperhidrosis - Hyperhidrosis Treatment Guidance  Kent & Medway PRGC May 2014  -  
13.3.1.4 Infliximab biosimilar - Flixabi® High-Cost Drugs    
13.3.1.4 Infliximab biosimilar - Flixabi® - Infliximab for the treatment of adults with psoriasis TA134
ICB commissioned - approval via Blueteq
NICE Jan 2008  
13.10 Ingenol mebutate -   Ingenol mebutate (Picato) Safety Alert  - discontinued due to  risk of skin malignancy  MHRA 
Drug Safety Update
Feb 2020 -
13. / 13.1/13.1.5
Moisture Damage Medway CCG Only - Prescribing Guidance for Barrier Creams 
MCH Nov 2018
Nov 2020
13.7.1 Ritlecitinib - (Litfulo®) High-Cost Drugs     
13.7.1 Ritlecitinib for treating severe alopecia areata in people 12 years and over TA958
ICB commissioned - approval via Blueteq supplied via Homecare
NICE Mar 2024  -
13.3.1.4  Tralokinumab High-Cost Drugs     
13.3.1.4  Upadacitinib High-Cost Drugs     

 

 

 

  

  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •